Sun Hit As US FDA Raises Fresh Concerns Over Key Halol Plant

Indian generic giant Sun Pharma says the US FDA has flagged up new potential violations of good manufacturing practices at the company's key Halol factory, which exports a large number of products to the crucial US market and had been expected to overcome its past compliance problems.

production line

Sun Pharmaceutical Industries Ltd.'s shares had been rising on investor optimism that US Food and Drug Administration inspectors would give the all-clear to the company’s flagship Halol plant after their visit last month to the factory, located in India's western Gujarat state.

But instead the FDA team found new potential breaches of good manufacturing practices at Halol, Sun Pharma disclosed Dec. 7...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from India

More from Asia